中国临床肿瘤学会小细胞肺癌专家委员会 1刘晓晴 2陆舜3
作者信息
- 2. 解放军总医院第五医学中心
- 3. 上海交通大学附属胸科医院
- 折叠
摘要
Abstract
Small cell lung cancer(SCLC),characterized by high aggressiveness,early metastasis,and poor progno-sis,has long been a major challenge in lung cancer treatment.In recent years,the advent of immune checkpoint inhibitors(ICIs)has significantly improved overall survival in patients with SCLC and has become a new standard of care;however,substantial room for further improvement in clinical outcomes remains.As an emerging T cell-targeted immunotherapy,delta-like ligand 3-T cell engager(DLL3-TCE)precisely directs T cells to attack tumor cells and have demonstrated breakthrough potential in the treatment of SCLC.Tarlatamab,a representative agent in this class,has been approved for clinical use,and multiple TCE agents are currently under clinical development.Although DLL3-TCE shows promising prospects in the clinical management of SCLC,as a novel therapeutic modality,many clinicians still lack an in-depth understanding of their mechanisms of action,appropriate patient populations,and clinical management.To standardize the clinical application of DLL3-TCE in China,the Small Cell Lung Cancer Expert Committee of the Chinese Society of Clinical Oncology convened a consensus panel to devel-op the Chinese Expert Consensus on Delta-like Ligand 3-T Cell Engager Therapy for SCLC based on evidence-based medicine and expert practical experience,with the aim of providing standardized guidance for the clinical use of DLL3-TCE agents.关键词
肺肿瘤/δ样配体3/T细胞衔接器/塔拉妥单抗/专家共识Key words
Lung neoplasms/Delta-like ligand 3/T cell engager/Tarlatamab/Expert consensus
